Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Astellas gets fifth action letter on modified-release tacrolimus

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Astellas Pharma receives another "approvable" letter for its once-daily formulation of its immunosuppressant Prograf (tacroliumus), dashing hopes of approval before a substance patent for the twice-daily formulation expired April 8. Prograf MR is under review for prophylaxis of organ rejection in both kidney and liver transplant patients. The Japanese firm received the second approvable letter for the liver transplant indication April 30; the kidney transplant indication got its second approvable letter in March. A heart transplant indication was deemed "not approvable" in January 2007. Astellas said it is "examining the future strategy" and working closely with FDA to better understand the issues raised. More time needed for Entereg review: After a three-month delay pushed back the user fee date for GlaxoSmithKline/Adolor's Entereg (alvimopan), FDA will not meet the scheduled May 10 action date, Adolor announces. After the Gastrointestinal Drugs Advisory Committee called the risk management plan inadequate in January, the firms submitted a new program in February. Entereg, indicated for postoperative ileus, has received two "approvable" letters since the NDA submission in 2004 (1Pharmaceutical Approvals Monthly November 2006, In Brief)

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts